Ironwood Pharmaceuticals
IRWD
145 hedge funds and large institutions have $1.79B invested in Ironwood Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 58 increasing their positions, 35 reducing their positions, and 15 closing their positions.
66% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 35
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
17% more capital invested
Capital invested by funds: $1.53B → $1.79B (+$261M)
7% more funds holding
Funds holding: 136 → 145 (+9)
2% more call options, than puts
Call options by funds: $17.5M | Put options by funds: $17.1M
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$13.2M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$12.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.7M |
| 4 |
BJCM
Blue Jay Capital Management
Los Angeles,
California
|
+$9.58M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$45.2M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$26M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$19.2M |
| 4 |
O
OrbiMed
New York
|
-$18.7M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$9.45M |
IRWD Hedge Fund Activity: Q2 2016 in Review
145 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2016, worth a combined $1.79B — up 17% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new IRWD positions and 15 closed out — a net gain of 9 holders — while 58 added to existing stakes and 35 trimmed.
The largest buyer was Granahan Investment Management, opening a new position worth an estimated $13.2M. The largest seller was Redmile Group, cutting an estimated $45.2M.
- 145 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2016, up from 136 in Q1 2016.
- Funds reported $1.79B of Ironwood Pharmaceuticals stock for Q2 2016, up 17% quarter-over-quarter.
- 24 funds opened new Ironwood Pharmaceuticals positions in Q2 2016 and 15 closed out, a net change of +9 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2016 was Granahan Investment Management, an estimated $13.2M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2016 was Redmile Group, an estimated $45.2M sold.
Based on aggregated 13F filings for Q2 2016.